Portfolio Lab

Bio-Rad Laboratories, Inc.

  • Stock
  • Ticker BIO-B
  • ISIN US0905721082
  • NYSE

Performance, volatility and drawdowns of Bio-Rad Laboratories, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

1-year return
+25.5%
5-year return p.a.
−12.7%
10-year return p.a.
+8.6%
Volatility p.a.
29.3%
Largest decline
−72.5%

Performance

BIO-BGlobal equities (VT)

$10,000 grew to $22,739. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −72.5% in 04/2025, measured from the peak in 09/2021. The old peak has not been reached again yet.

Annual returns

Best year 2019 at +60.7%, weakest 2022 at −44.0%. 5 of 9 full years were positive. * partial year.

Compared with Global equities

Since 11/2016BIO-BGlobal equities (VT)
Return p.a.+8.6%+11.3%
Volatility p.a.29.3%15.1%
Largest decline−72.5%−34.2%
Return per unit of risk0.290.74
$10,000 grew to$22,739$29,042

Bold: the better value in each row. Return per unit of risk: return p.a. divided by volatility p.a. Correlation of monthly returns with Global equities: 0.41 (1 would mean they moved in lockstep).

More stocks of similar size

Test BIO-B in your own portfolio

Mix it with other securities, set recurring investments and costs, compare against a broad equity ETF. No account needed.

Open in backtest

Frequently asked questions

How has BIO-B performed since 11/2016?

$10,000 grew to $22,739 by 20 Nov 2026, which is +8.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is BIO-B?

Volatility was 29.3% per year, measured on monthly returns. The largest decline from a peak was −72.5%, with the low in 04/2025.

How does BIO-B compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, BIO-B returned +8.6% at 29.3%. The correlation of monthly returns was 0.41; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.